Black patients and other minorities tend to be diagnosed at later stages of the disease, which would exclude them from use of Leqembi. Few Black people were included in the main trial of the drug.

Racial disparities in drug trials, and disparities in overall medical care, among other factors, make the recently-approved Alzheimer’s break-through drug lecanemab less likely to benefit African Americans.